Trial Profile

Phase 2b randomized triple combination trial of Motixafortide in patients with first-line metastatic pancreatic ductal adenocarcinoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Motixafortide (Primary) ; Antineoplastics; Programmed cell death-1 ligand-1 inhibitors
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions

16 Aug 2022 According to a BioLineRx media release, the company expects to initiate this study in 2023.
01 Jul 2022 New trial record
28 Jun 2022 According to a BioLineRx media release, the company has entered into a collaboration agreement with GenFleet Therapeutics to initiate this trial based on results from KEYNOTE-202 study. GenFleet will fully fund, design and execute this trial. BioLineRx will supply Motixafortide, while GenFleet will supply the other study drugs. Trial oversight will be administered by a Joint Development Committee.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com